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MicroRNAs (miRNAs) are highly conserved small non-coding
RNAs that act as post-transcriptional regulators of target
mRNA. In this study, we sought to identify the microRNA
underlying local inflammation in a murine model of chronic
kidney disease (CKD). In microarray analysis of kidneys, the
expression of miR-146a/b was elevated in B6.MRLc1 CKD
mice that spontaneously develop renal inflammation with
age. Primary-microRNA analysis found that elevated
miR-146a/b expression in the kidneys of B6.MRLc1 mice
was mainly derived from miR-146a rather than miR-146b,
and this expression increased with the development of CKD.
Histopathological scores for glomerular and interstitial
lesions, mRNA expression of inflammatory mediators, and
macrophage infiltration were significantly higher in
B6.MRLc1 than C57BL/6 mice and were positively correlated
with miR-146a expression. In situ hybridization and laser
microdissection–RT-PCR showed that miR-146a expression in
interstitial lesions containing inflammatory cells was higher
than in the glomerulus. The increased expression of the
inflammatory-associated genes RELA, IRAK1, IL1B, IL10, and
CXCLs was noted in miR-146a/b-silenced human monocytes.
The amount of miR-146a was higher in urine sediments of
B6.MRLc1 than of C57BL/6 mice. Thus, miR-146a expression
in the kidneys and its urinary excretion was specifically
associated with the development of interstitial lesions
and correlated with inflammatory cell infiltration.
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The global increase in patients contracting chronic kidney
disease (CKD) is a serious problem given their higher
mortality and increased risk of cardiovascular disease with
aging.1 One of the principal primary causes of CKD is
chronic inflammation of the glomerulus and tubulointer-
stitium. Anti-inflammatory therapies can improve the out-
come in CKD patients.2,3 During inflammation, cytokines
and chemokines function as disease-exacerbating factors, and
their usefulness as biomarkers in CKD has been examined in
clinicopathological studies.3,4 In addition, the gene expres-
sion of inflammatory mediators is strongly affected by aging,
resulting in epigenetic alternations, e.g., DNA methylation
and RNA interference via microRNAs (miRNAs).5 Impor-
tantly, chronic inflammation is also affected by these
epigenetic processes and environmental factors, causing
changes in the expression of inflammatory mediators.6 These
processes are also related to various lifestyle diseases
including cardiovascular disease, diabetes, and autoimmune
disorders.7
miRNAs are highly conserved small non-coding RNAs
that function as posttranscriptional regulators by binding to
the complementary 30-untranslated region of target mRNA.8
miRNA dysfunction is associated with the development of
various diseases, such as diabetes and inflammatory disease.8
miRNAs participate in innate immunity and inflammation
by controlling cell growth, differentiation, proliferation, and
death.9 In particular, some miRNAs, e.g., miR-146a/b and
miR-155, participate in inflammation by regulating the Toll-
like receptor/interleukin (IL)-1b receptor signaling cascades
subsequent to the activation of the nuclear factor-kappa B
(NF-kB) signaling pathway.10 Interestingly, RNA interference
by miRNAs is important in the maintenance of renal
homeostasis. Mice lacking Dicer, an essential endoribonu-
clease for miRNA production, develop glomerular and
tubular injuries with proteinuria and subsequently die from
renal failure.11 In addition, some miRNAs, e.g., miR-17 and
miR-210, affect the development of polycystic kidney disease
and renal cell carcinoma in humans and animal models,
respectively.12,13 However, there is no obvious evidence
indicating the identity of miRNAs associated with chronic
renal inflammation that could be used as biomarkers.
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We previously created B6.MRLc1 CKD mice.14–17 With
aging, B6.MRLc1 spontaneously develop chronic kidney
inflammation due to hyper-inflammatory responses and
develop membranoproliferative glomerulonephritis and in-
terstitial lesions with mononuclear cell infiltration, similar to
human CKD.14,16 As B6.MRLc1 is a C57BL/6-based congenic
strain carrying a telomeric region of chromosome 1 contain-
ing immune disease susceptibility genes derived from the
inflammation-prone MRL/MpJ, the genetic references for
B6.MRLc1 are clear, and secondary genetic effects are
minimized during their analysis.16 Therefore, B6.MRLc1 are
a useful model to discover new CKD disease-associated
factors.15–17
To clarify the miRNA-modulating pathogenesis of CKD,
we investigated the kidneys of B6.MRLc1 by using patholog-
ical and comprehensive microarray analyses. We identified
miR-146a as an important regulator of local chronic
inflammation. Our findings provide new insights into the
molecular pathogenesis of chronic kidney inflammation and
will contribute to the development of therapeutic strategies
for CKD.
RESULTS
Altered miRNA expression in the CKD model
Table 1 shows a summary of the microarray analysis for 511
miRNAs in the kidneys of 12-month-old mice. miR-146a
showed the highest expression level in B6.MRLc1 kidneys
(2.2-fold vs. C57BL/6), with miR-146b ranked third (Table 1).
All miRNAs had values 40.75 (fold increase vs. C57BL/6),
and there were no downregulated miRNAs in B6.MRLc1
(Supplementary Data S1 online). In TaqMan-based real-time
PCR analysis, miR-146a was expressed at a higher level in
B6.MRLc1 than in C57BL/6 (range, 0.9–5.5-fold vs. C57BL/6,
Figure 1a). miR-146a and -146b differ by two nucleotides in
mice and humans (Supplementary Data S2 online), and a
specific TaqMan probe can detect B0.3% of each miRNA in
this condition.18 The functions of miR-146a and -146b
overlap to some extent, and they have similar mRNA targets
Table 1 | Summary of results in microarray analysis
Rank Fold change miRBaseID (mouse) Name (mouse) Name (human)
1 2.21 MIMAT0000158 mmu-miR-146a hsa-miR-146a
2 1.91 MIMAT0000530 mmu-miR-21 hsa-miR-21
3 1.88 MIMAT0003475 mmu-miR-146b hsa-miR-146b-5p
4 1.75 MIMAT0000155 mmu-miR-142-3p hsa-miR-142-3p
5 1.48 MIMAT0000154 mmu-miR-142-5p hsa-miR-142-5p
6 1.43 MIMAT0000548 mmu-miR-322 —
7 1.42 MIMAT0000133 mmu-miR-101a hsa-miR-101
8 1.41 MIMAT0000151 mmu-miR-140 hsa-miR-140-5p
9 1.40 MIMAT0000665 mmu-miR-223 hsa-miR-223
10 1.39 MIMAT0000526 mmu-miR-15a hsa-miR-15a
11 1.38 MIMAT0003188 mmu-miR-503 —
12 1.35 MIMAT0000616 mmu-miR-101b —
13 1.31 MIMAT0000137 mmu-miR-126-5p hsa-miR-126
14 1.31 MIMAT0000536 mmu-miR-29c hsa-miR-29c
15 1.30 MIMAT0003484 mmu-miR-720 hsa-miR-720
16 1.30 MIMAT0000127 mmu-miR-29b hsa-miR-29b
17 1.28 MIMAT0000156 mmu-miR-144 hsa-miR-144
18 1.27 MIMAT0000225 mmu-miR-195 hsa-miR-195
19 1.27 MIMAT0000513 mmu-miR-19b hsa-miR-19b
20 1.27 MIMAT0000121 mmu-let-7g hsa-let-7g
21 1.25 MIMAT0001081 mmu-miR-196b hsa-miR-196b
22 1.25 MIMAT0003733 mmu-miR-665 —
23 1.24 MIMAT0000153 mmu-miR-141 hsa-miR-141
24 1.24 MIMAT0000518 mmu-miR-196a hsa-miR-196a
25 1.24 MIMAT0000527 mmu-miR-16 hsa-miR-16
26 1.24 MIMAT0000654 mmu-miR-32 hsa-miR-32
27 1.23 MIMAT0000229 mmu-miR-199a-5p —
28 1.23 MIMAT0000220 mmu-miR-190 hsa-miR-190
29 1.23 MIMAT0003190 mmu-miR-291b-3p —
30 1.21 MIMAT0003495 mmu-miR-705 —
31 1.21 MIMAT0001094 mmu-miR-412 hsa-miR-412
32 1.21 MIMAT0004934 mmu-miR-872 hsa-miRPlus-D1090
33 1.21 MIMAT0000517 mmu-miR-192 hsa-miR-192
34 1.20 MIMAT0003727 mmu-miR-374 hsa-miR-374b
35 1.20 MIMAT0000141 mmu-miR-130a hsa-miR-130a
36 1.19 MIMAT0000545 mmu-miR-98 hsa-miR-98
37 1.19 MIMAT0003172 mmu-miR-542-3p hsa-miR-542-3p
38 1.18 MIMAT0003505 mmu-miR-714 —
39 1.18 MIMAT0000651 mmu-miR-19a hsa-miR-19a
40 1.17 MIMAT0009445 mmu-miR-1274a hsa-miR-1274a
Values: B6.MRLc1 vs. C57BL/6. —, absent in human.
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(miRBase; http://www.mirbase.org/). To clarify the origin of
elevated miR-146a/b expression, we analyzed primary-
miRNA expression. miR-146a and primary-miR-146a ex-
pression was higher in B6.MRLc1 kidneys (Figure 1b and c)
and increased with aging, with an especially marked increase
between 9 and 12 months (Figure 1c). We therefore focused
on miR-146a as a CKD-associated miRNA.
Correlations between renal pathology and miR-146a
expression in the kidneys of the CKD model
Figure 2 shows the renal histopathology and miR-146a
expression in B6.MRLc1 kidneys. B6.MRLc1 with relatively
high levels of miR-146a expression (1.7-fold vs. C57BL/6)
showed severe glomerular lesions (Figure 2b). Furthermore,
B6.MRLc1 with remarkably high levels of miR-146a expres-
sion (3.1-fold vs. C57BL/6) showed severe interstitial
lesions with cell infiltration, tubular atrophy (Figure 2c),
interstitial fibrosis (Figure 2f), and glomerular lesions.
These mice had a larger F4/80 (macrophage marker)-positive
area and an increased number of CD3 (T-cell marker)-
positive cells and IL-1 family member 6 (IL-1F6, damaged
tubule marker)-positive tubules (Figure 2h, i, k, l, q, and r).
The correlation between miR-146a expression and the
infiltration of Gr-1 (granulocyte marker)-positive cells was
unclear (Figure 2m–o). No obvious lesions were observed
in mice with relatively low levels of miR-146a expression
(0.4-fold vs. C57BL/6, Figure 2a, d, g, j, m, and p). B220
(B-cell marker)-positive cells were rarely observed (data
not shown).
Corresponding to the renal histopathological findings,
B6.MRLc1 showed significantly higher glomerular and inter-
stitial lesion scores, number of CD3-positive and Gr-1-positive
cells, F4/80-positive area, and number of IL-1F6-positive
tubules than C57BL/6 (Figure 3a, d, g, j, m, and p). The
glomerular lesion, interstitial lesion, and CD3 scores in
B6.MRLc1 gradually increased with aging (Figure 3b, e, and
h), and those of F4/80 and IL-1F6 were markedly increased at
12–14 months. The Gr-1 score did not change remarkably with
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Figure 1 |miR-146a expression in kidneys. (a) Comparison of miR-146a expression between 12-month-old C57BL/6 and B6.MRLc1 mice
(n¼ 4). (b) Comparison of primary-miRNA expression between 12-month-old C57BL/6 and B6.MRLc1 mice (n¼ 4). (c) Time-course
expression in B6.MRLc1 mice (nX4 at each age). Expression values are expressed as a fold increase to those of C57BL/6 mice at 12 months.
Values¼means±s.e. *Mann–Whitney U-test (Po0.05).
Figure 2 |Correlations between renal histopathology and miR-146a expression. The vertically arranged figures are derived from the
same individuals. Panels g–r are light micrographs of immunofluorescence. (a, d, g, j,m, and p) Renal cortices from B6.MRLc1 mice with miR-
146a expression values¼ 0.4. Histopathological changes are not clear, and F4/80-, CD3- Gr-1-, and IL-1F6-positive cells are scarcely observed
(m, arrow). (b, e, h, k, n, and q) Renal cortices from B6.MRLc1 mice with miR-146a expression values¼ 1.7. Glomerular lesions, e.g.,
glomerular hypertrophy, expansion of the mesangial matrix, and increased number of glomerular cells, and mild tubule interstitial lesions
(arrowheads), e.g., mononuclear cell infiltration, are observed (b and e). F4/80-positive cells are observed in interstitial lesions
(h, arrowheads). CD3-positive mononuclear cells are observed in the glomerulus and interstitium (k, arrows). Gr-1-positive cells are mainly
observed in the glomerulus (n, arrow). IL-1F6-positive reactions are observed in the cytoplasm and nucleus of tubular cells (q). (c, f, i, l, o,
and r) Renal cortices from B6.MRLc1 mice with miR-146a expression values¼ 3.1. Glomerular lesions and tubulointerstitial lesions are the
most severe (compare a–c). Fibrotic areas are increased in the interstitial lesions (blue regions, f). The number or area of positive reactions of
F4/80, CD3, and IL-1F6, except for Gr-1, are remarkably increased compared with the other two mice. AS, aniline blue stain; CD3, T-cell
marker; F4/80, macrophage marker; Gr-1, granulocyte marker; IL-1F6, tubular damage marker; PAS, periodic acid-Schiff stain. Bars¼ 50mm.
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aging (Figure 3n). Correlation analysis indicated that the
glomerular lesion, interstitial lesion, F4/80, and IL-1F6 scores,
but not CD3 and Gr-1, were significantly and positively
correlated with miR-146a expression (Figure 3c, f, l, and r).
We analyzed the expression of cell-specific mRNAs,
including Cd3e (T cells), Ptprc (B cells), Cd68 (macrophages),
and S100a4 (fibroblasts) associated with the development of
renal lesions (Figure 4). The expression of Cd68 and S100a4
a PAS, miR-146a = 0.4 PAS, miR-146a = 1.7 PAS, miR-146a = 3.1
AS, miR-146a = 1.7AS, miR-146a = 0.4 AS, miR-146a = 3.1
F4/80, miR-146a = 0.4 F4/80, miR-146a = 1.7 F4/80, miR-146a = 3.1
CD3, miR-146a = 0.4 CD3, miR-146a = 1.7 CD3, miR-146a = 3.1
GR-1, miR-146a = 0.4 GR-1, miR-146a = 1.7 GR-1, miR-146a = 3.1
IL-1F6, miR-146a = 0.4 IL-1F6, miR-146a = 1.7 IL-1F6, miR-146a = 3.1
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was significantly higher in B6.MRLc1 than in C57BL/6
(Figure 4g, h, j, and k) at 10–12 months of age (Figure 4h and
k), and was significantly and positively correlated with miR-
146a expression (Figure 4i and l). There was no significant
pathological correlation between CKD and Cd3e or Ptprc
expression (Figure 4a–f).
Relationship between the expression of inflammatory
mediators and miR-146a in the kidneys of the CKD model
We analyzed the mRNA expression of Cxcl2, Il1b, Il1rn, Il1f6,
and Il10 associated with local renal inflammation; we
previously identified these as disease-associated factors in
comprehensive analyses of murine nephritis models.16,19
They were all expressed at a significantly higher level in
B6.MRLc1 than in C57BL/6 (Figure 5a, d, g, j, and m).
Although their expression increased with aging, their levels
varied and differed (Figure 5b, e, h, k, and n); furthermore,
their expression was significantly and positively correlated
with miR-146a expression (Figure 5c, f, i, l, and o).
Localization of miR-146a-expressing cells in the kidneys of
the CKD model
In situ hybridization was used to identify miR-146a-
expressing cells (Figure 6). In B6.MRLc1 kidneys that
developed glomerular and interstitial lesions, we observed
positive signals for miR-146a in interstitial lesions (Figure 6b
and e). In addition, mononuclear cell infiltrations were
observed in the same lesions on serial sections (Figure 6d
and e). A previous study reported that immune cells
expressed miR-146a.20 In the enlarged mediastinal
lymph nodes of B6.MRLc1, which were used as positive
controls, some mononuclear cells showed strong signals
(Figure 6g and h).
To gain further evidence for the localized expression of
miR-146a, we used laser microdissection (LMD)–RT-PCR to
isolate glomerular lesion and interstitial lesions, including
infiltrating mononuclear cells, from histological sections of
B6MRLc1 kidneys (Figure 7a–d). RT-PCR analysis revealed
strong Cd68 expression in interstitial lesions compared with
glomerular lesions, and the validity of LMD was confirmed
by the detection of Il1f6 expression (Figure 7e). mRNA
expression associated with NF-kB signaling regulated by
miR-146a was also detected in both lesions, and Nfkb2
expression was stronger in interstitial lesions than in
glomerular lesions (Figure 7e). miR-146a expression was
higher in interstitial lesions than in glomerular lesions
(Figure 7f).
In vitro silencing of miR-146a/b expression in monocytes
In THP-1 cells derived from human monocytes, miR-146a/b
expression was silenced with an anti-miR miRNA inhibitor
(Figure 8). Transfection efficiency was confirmed by the
detection of carboxyfluorescein in a negative control (Figure
8a). miR-146a and miR-146b-5p (homolog to murine miR-
146b) expression was markedly decreased by the inhibitor
(Figure 8d); therefore, we eliminated the overlapping
functions of these miRNAs. We observed no obvious
morphological changes in miR-146a/b-silenced monocytes
(Figure 8b and c). There was no significant change in the
mRNA expression of NF-kB family members, except for v-rel
reticuloendotheliosis viral oncogene homolog A (RELA), in
miR-146a/b-silenced monocytes (Figure 8e). The mRNA
expression of the predicted targets of miR-146a/b, e.g., tumor
necrosis factor receptor-associated factor 6 (TRAF6) and IL-1
receptor-associated kinase 1 (IRAK1), which are upstream
regulators of the NF-kB signaling pathway, was slightly
increased in miR-146a/b-silenced monocytes (Figure 8e), and
the protein levels of TRAF6 were not changed, but those of
IRAK1 were significantly higher in miR-146a/b-silenced
monocytes (Figure 8f). The mRNA expression of inflamma-
tory genes, e.g., IL1B, IL10, CXCL2, and CXCL3, was elevated
(Figure 8g).
Urine levels of miR-146a in the CKD model
The levels of miR-146a were assessed in bladder urine from
the mice. Higher levels of miR-146a expression were observed
in urine sediments than in the supernatants (Figure 9a). In
addition, B6.MRLc1 showed higher miR-146a expression in
urine sediments than C57BL/6 (Figure 9b).
DISCUSSION
Relationship between altered miR-146a expression and CKD
development
Microarray and primary-miRNA expression analyses revealed
that miR-146a showed the highest expression level in the
kidneys of the aged CKD model. This model shows mild
glomerular lesions in 6- to 8-month-old mice, whereas
interstitial lesions and severe glomerular lesions are observed
in 10- to 12-month-old mice.14,16 We clarified that the
expression of miR-146a increased with aging, especially
between 10 and 12 months with real-time PCR analysis. The
infiltration of neutrophils in glomerular lesions, monocytes/
macrophages in interstitial lesions, and T cells in both lesions
are also observed. miR-146a expression was significantly
correlated with the interstitial lesion scores, including F4/80-
positive areas and IL-1F6-positive damaged renal tubules,
but not with the number of CD3- or Gr-1-positive cells.
Similarly, the mRNA expression of monocyte/macrophage-
specific markers and Il1f6 was correlated with miR-146a
expression. Neutrophil infiltrations are reportedly more
closely correlated with glomerular lesions than interstitial
lesions in SCG/Kj glomerulonephritis mice.21 In addition, the
number of interstitial F4/80-positive monocytes/macro-
phages increased with the development of chronic inflam-
mation and renal fibrosis following ureteral obstruction.22
We previously demonstrated that inflammatory Il1f6 mRNA
expression in the collecting ductal epithelium was increased
by its coculture with spleen cells, and that mononuclear cell
infiltrations were observed around IL-1F6-positive tubules in
CKD mice.16 We clearly demonstrated that miR-146a-
expressing cells were mainly found in interstitial lesions
rather than in glomerular lesions in our CKD model;
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Figure 3 |Histopathological parameters and miR-146a expression in kidneys. (a, d, g, j, m, and p) Comparison between 12-month-old
C57BL/6 and B6.MRLc1 mice (n¼ 4). Values¼means±s.e. *Mann–Whitney U-test (Po0.05). (b, e, h, k, n, and q) Time-course analysis in
B6.MRLc1 mice (nX4 at each age). Values¼means±s.e. (c, f, i, l, o, and r) Correlation between the histopathological scores and miR-146a
expression (n¼ 24). Values¼means±s.e. Spearman’s correlation test (Po0.001) was used to analyze the correlation between two
parameters. CD3, T-cell marker; F4/80, macrophage marker; GL, glomerular lesion; Gr-1, granulocyte marker; IL, interstitial lesion; IL-1F6,
tubular damage marker; ND, not detected.
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therefore, it is strongly suggested that the main source
of the increased miR-146a expression in CKD kidneys is
interstitial infiltrating cells, especially those of the monocytic
lineage.
Relationship between altered miR-146a expression and
inflammatory mediators
We clarified the positive correlation between miR-146a
expression and inflammatory mediators in the CKD model.
We previously observed their markedly upregulated mRNA
expression during comprehensive analysis of gene expression
in murine models of inflammatory kidney disease.16,19 IL-1b
is a primary inflammatory cytokine produced by a wide
range of cells, including renal parenchymal and infiltrating
cells, and is a mediator of acute and chronic inflammation.23
Conversely, the function of IL-1b is in competition with the
IL-1 receptor antagonist (IL-1RA, coded by Il1rn).23 IL-1a/b-
deficient mice, which were induced by renal ischemic
injuries, have reduced tubular necrosis levels and mono-
cyte/macrophage and neutrophil infiltration in kidneys, and
the reverse was true in IL-1RA-deficient mice.24 The renal
elevation of CXCL2 expression (macrophage inflammatory
protein-2, coded by Cxcl2) was correlated with the infiltra-
tion of inflammatory cells, e.g., neutrophils and macro-
phages, in glomerular and interstitial lesions.25,26 In lupus
nephritis patients, IL-10 was produced by cells infiltrating
glomerular and interstitial lesions or the tubular epithe-
lium.27 These findings indicate that these cytokines and
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chemokines, which were correlated with miR-146a expression
in the present study, were associated with inflammatory cell
infiltration. Therefore, we considered that the local increase
of miR-146a and these factors participated in the chronic
inflammatory process, especially the infiltration of cells in
interstitial lesions.
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Role of miR-146a in chronic renal inflammation
Elevated miR-146a expression was reported in peripheral
blood mononuclear cells and synovial fibroblasts of rheuma-
toid arthritis patients and in splenic T cells of murine lupus
models.28 In addition, we demonstrated the increased local
expression of miR-146a in interstitial lesions containing
mononuclear cell infiltrations. Furthermore, our data re-
vealed the pathological correlation between the expression of
miR-146a and cytokines, including the IL-1 family, in CKD
kidneys. Expression of miR-146a was reportedly increased in
human monocytes stimulated with lipopolysaccharide and
cytokines, e.g., IL-1b and tumor necrosis factor-a.20 miR-
146a was also associated with tumorigenesis, innate im-
munity, and inflammatory responses, including infections
and autoimmune diseases in humans and rodents.29 TRAF6
and IRAK1 are known targets of miR-146a/b, and these two
adaptor molecules of the Toll-like receptor/IL-1b receptor
signaling pathway regulate the expression of inflammatory
cytokines, e.g., IL-1b and tumor necrosis factor-a, through
their NF-kB activity.29 In our study of miR-146a/b-silenced
monocytes, although the changes in mRNA expression
associated with NF-kB signaling were not significant, those
of inflammatory mediators, e.g., IL1B, IL10, and CXCLs, were
altered. These data indicate the possibility that miR-146a has
unknown endogenous targets that have an important role in
regulating inflammatory responses. In particular, miR-146a/b
silencing strongly increased IL-10 mRNA expression, which
is an anti-inflammatory cytokine produced by macrophages.
From these findings, we considered that this upregulation
compensated for the anti-inflammatory activity of miR-146a/b.
Recently, the macrophage sub-populations that resolved
chronic inflammation were discussed, and their important
role in the repair of renal fibrosis has been investigated.30
In vivo, miR-146a-expressing cells, including macrophages in
inflammatory lesions, might participate in the termination of
chronic inflammation through NF-kB-dependent or -inde-
pendent signaling pathways.
Urinary levels of miR-146a in CKD
The altered expression of miRNAs in urinary sediments has
been investigated in some diseases.31,32 In IgA nephropathy, a
significant correlation was identified between the number of
urine macrophages and the activity index of renal biopsies,
proteinuria, and urine white blood cell counts.33 In addition,
C57BL/6a cb
B6.MRLc1
B6.MRLc1
B6.MRLc1
B6.MRLc1
B6.MRLc1B6.MRLc1
B6.MRLc1B6.MRLc1
T T
G G
GGG
A AA
VV V
d e f
g h i
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we observed a higher level of urinary miR-146a in sediments
than in the supernatants from CKD mice, indicating that
CKD urine contained miR-146a-expressing cells, and that the
noninvasive evaluation of urinary miR-146a expression
might represent the pathological activity of CKD and renal
dysfunction. Interestingly, as the sequence of miR-146a is
identical between humans and rodents, analysis of the
relationship between urinary miR-146a levels and renal
histopathology and function or the effects of the therapeutic
administration of miR-146a in rodents would verify its
usefulness in clinical nephrology.
In conclusion, the present study clarified the increased
expression of miR-146a in local inflammatory lesions. These
data strongly suggested the role of miR-146a in the local
regulation of inflammatory mediators, and our findings
provide new insights into the molecular pathogenesis of
chronic kidney inflammation and could contribute to the
development of therapeutic strategies for CKD.
MATERIALS AND METHODS
Tissue preparation
We followed the Guidelines for the Care and Use of Laboratory
Animals of Hokkaido University, Graduate School of Veterinary
Medicine (approved by the Association for the Assessment and
Accreditation of Laboratory Animal Care International). Female
B6.MRLc1 (68–82) mice (previously called B6.MRLc1 (82–100))
were bred in our laboratory.14 Female C57BL/6 mice were purchased
from Japan SLC (Hamamatsu, Japan). They were maintained under
specific pathogen-free conditions. Under deep anesthesia, urine was
collected by bladder puncture, mice were killed by exsanguination
from the carotid arteries, and the kidneys were collected. A part of
each sample was fixed in 4% paraformaldehyde at 4 1C for
histopathological analysis, in situ hybridization, and for LMD. The
remaining fresh parts were stored in RNAlater solution (Ambion,
Austin, TX). Urine was stored at 80 1C.
Histopathological analysis
Paraffin-embedded kidney sections were stained with periodic acid-
Schiff. For the indices of glomerular lesions, digital images of five
glomeruli per kidney were prepared, and the number of nuclei per
glomerulus was measured using Adobe Photoshop CS4 (Mountain
View, CA).19 For the indices of interstitial lesions, digital images of
the kidney sections stained with aniline blue were prepared, and the
blue-stained area per total area of the interstitial region was
measured using the ImageJ ver. 1.32j (NIH, Bethesda, MD).
Immunohistochemistry and immunofluorescence
Immunohistochemistry of the paraffin-embedded kidney sections
was performed with unlabeled anti-CD3 (Nichirei, Tokyo, Japan),
anti-B220 (Cedarlane, Homby, Ontario, Canada), anti-F4/80
(Cedarlane), anti-Gr-1 (R&D Systems, Minneapolis, MN), and
anti-IL-1F6 antibodies (R&D Systems). We used 3,30-diaminoben-
zidine tetrahydrochloride-H2O2 solution for signal development.
The number of CD3-, B220-, or Gr-1-positive cells and the number
of IL-1F6-positive renal tubules in five kidney sections were
measured, and their mean number was expressed as the positive
cell number or positive tubule number, respectively. To quantify the
F4/80-positive area, kidney sections stained with immunohisto-
chemistry were prepared, and the 3,30-diaminobenzidine-stained
area per total area of the interstitial region was measured using
ImageJ (NIH). For immunofluorescence, FITC-labeled goat IgG for
F4/80 and Gr-1 (Zymed, San Francisco, CA), FITC-labeled donkey
IgG for CD3 (Abcam, Cambridge, MA), and TRITC-labeled rabbit
IgG for IL-1F6 (Zymed) were applied as secondary antibodies.
In situ hybridization
A 50- and 30-double digoxigenin-labeled miRCURY LNA miRNA
Detection Probe (Exiqon, Vedbaek, Denmark) was used for in situ
hybridization analysis (Supplementary Data S2 online). Deparaffi-
nized proteinase K-digested sections were incubated with prehy-
bridization and then hybridization buffers containing 40%
deionized formamide, 10mmol/l Tris-HCl (pH 7.4), 1 Denhardt’s
solution (Sigma, St Louis, MO), 10% dextran sulfate, 600mmol/l
NaCl, 1mmol/l EDTA, and 0.5 mmol/l probe for 24 h at 40 1C. For
the negative control, salmon testis DNA (10 mg/ml) and yeast rRNA
(20mg/ml) were added to the hybridization buffer instead of the
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antisense control. After washing with standard saline citrate, the
sections were incubated with anti-digoxigenin Fab fragments
conjugated to alkaline phosphatase (Roche Diagnostics, GmbH,
Mannheim, Germany). The signal was detected with a color
substrate solution (Roche Diagnostics) containing nitroblue tetra-
zolium and X-phosphate.
LMD
LMD was performed as previously reported.17 First, 5-mm thick
paraffin-embedded kidney sections were mounted on glass slides
precoated with LMD (Meiwafosis, Osaka, Japan). After deparaffi-
nization using xylene and rehydration in ethanol, the sections were
washed with water and stained with toluidine blue. LMD was
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performed on the glomerular and interstitial lesions with Ls-Pro300
(Meiwafosis) according to the manufacturer’s protocol.
miRNA silencing in THP-1 cells
To suppress the expression of target miRNA, we used an anti-miR
miRNA inhibitor that was designed to inhibit endogenous miRNA
activity as a small interfering RNA (ID: AM10722; Ambion). In
preliminary study, we confirmed that this inhibitor silenced miR-
146a and mi-R146b-5p. First, THP-1 cells (Dainippon Sumitomo
Pharma, Osaka, Japan) derived from human monocytes were
cultured with RPMI1640 medium containing 10% fetal bovine
serum without antibiotics. After culture for 24 h, the medium was
changed to a mixture of Lipofectamine (Invitrogen, Carlsbad, CA)
and Opti-MEM (Invitrogen) containing a carboxyfluorescein-
labeled anti-miR negative control or the anti-miR miRNA inhibitor.
After culture for 6 h, the medium was changed to RPMI1640 medium
containing 10% fetal bovine serum and 1% penicillin/streptomycin.
After 24 h, the cultured cells were analyzed. The transfection effi-
ciency of the inhibitor was confirmed by the detection of the
fluorescence of the carboxyfluorescein-labeled anti-miR negative
control according to the manufacturer’s instructions (Figure 8a).
Purification of total RNA
Total RNA was isolated from kidneys and cultured cells with the
TRIzol reagent (Invitrogen). Purified total RNA was treated with
DNase (Nippon Gene, Tokyo, Japan). Total RNA was purified from
urine (20 ml) and LMD samples with RNAqueous (Ambion)
according to the manufacturer’s instructions. Analysis of urine was
performed by dividing the samples into supernatant and sediment.
Microarray analysis of miRNA
Using total RNA extracted from the kidneys (two samples) of
12-month-old B6.MRLc1 (n¼ 4) and C57BL/6 (n¼ 4) mice, the
expression of 511 miRNAs was profiled using Exiqon’s miRCURY
LNA Array miRNA profiling service (Filgen, Nagoya, Japan). Briefly,
RNA samples were checked for RNA integrity on a Bioanalyzer2100
(Agilent Technologies, Wilmington, DE), labeled with Hy3, and
hybridized to miRCURY LNA Arrays v.11.0. Slides were scanned
using a laser scanner (Molecular Devices, Union City, CA), and the
images were digitized with Array-Pro Analyzer Ver. 4.5 (Media
Cybernetic, Silver Spring, MD). Finally, data were normalized and
expressed as fold increase vs. those from C57BL/6 mice with the
MicroArray Data Analysis Tool Ver. 3.2 (Filgen).
RT-PCR and real-time PCR
Purified total RNA was reverse-transcribed with a reaction mixture
containing random primers (Promega, Madison, WI) and Rever-
TraAce (Toyobo, Osaka, Japan). PCR was performed with ExTaq
(Takara, Tokyo, Japan). The specific primers used are shown in
Supplementary Data S2 online. Quantitative real-time PCR analysis
was performed using the Brilliant SYBR Green QPCR Master Mix
(Stratagene, La Jolla, CA) and a real-time thermal cycler (MX 3000;
Stratagene). The primers used were the same as those for RT-PCR
(Supplementary Data S2 online). ROX dye (Stratagene) was
included in each reaction to normalize the non-PCR-related
fluctuations in fluorescence. The amplification specificity of all
PCR reactions was confirmed by melting curve analysis. Non-
template controls were included for each primer pair to assess for
contaminants. The expression data were normalized to the expres-
sion of housekeeping genes.
RT- and TaqMan-based real-time PCR
Total RNA from kidneys, cells, urine sediment, and supernatant, and
LMD samples was reverse-transcribed using miRNA-specific stem-
loop RT primers, RTase, RT buffer, dNTPs, and RNase inhibitor
according to the manufacturer’s instructions (Applied Biosystems;
ABI, Foster City, CA). For primary-miRNA analysis, cDNA was
synthesized as described earlier. Real-time PCR was performed on
the resulting cDNA using miRNA-specific TaqMan primers (ABI,
Supplementary Data S2 online) and TaqMan Universal PCR Master
Mix (ABI) in an MX3000 real-time PCR system (Stratagene). We
used sno-202 as an endogenous housekeeping control for data
normalization of miRNA levels.
Immunoblotting
THP-1 cells were homogenized using RIPA lysis buffer (Santa Cruz
Biotechnology, Santa Cruz, CA). Soluble proteins were extracted by
10,000 g centrifugation for 10min at 4 1C. Twofold concentrated
SDS-sample buffer was added to the samples and heated at 100 1C
for 3min. Electrophoresis was performed on 12.5% polyacrylamide
gels (e-PAGEL; ATTO, Tokyo, Japan), and proteins were transferred
to polyvinylidene fluoride membranes (ATTO) at 1mA/cm2 for 1 h.
Blocking was performed in 1 blocking buffer (Sigma) at room
temperature for 1 h. For primary antibodies, rabbit anti-actin (Santa
Cruz Biotechnology), anti-TRAF6 (Abnova, Taipei, Taiwan), or
IRAK1 (Santa Cruz Biotechnology) antibodies were applied at 4 1C
overnight. After washing with Tris-buffered saline/0.1% Tween-20,
HRP-labeled goat anti-rabbit IgG (Santa Cruz Biotechnology) was
reacted at room temperature for 1 h. Immunodetection was
performed by Immobilon Western Detection Reagent (Millipore,
Schwalbach, Germany). Band intensity was measured by Image J
and was normalized by that of Actin.
Statistical analysis
The results were expressed as the mean±s.e. and analyzed using the
nonparametric Mann–Whitney U-test (Po0.05). Spearman’s corre-
lation test (Po0.05) was used to analyze the correlation between
two parameters.
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